Department of Medicine, Baylor College of Medicine, Houston, TX, USA
Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):516-25. doi: 10.1177/1074248414529620. Epub 2014 May 1.
Hypertension is the most important cardiovascular risk factor. We have witnessed a significant improvement in hypertension treatment and control and an impressive growth in the pharmacologic options available to clinicians and hypertension specialists. With up to a third of patients with hypertension not at the recommended goal blood pressures, it is critically important to develop novel therapeutic approaches to better treat hypertension. This review will explore the ever-expanding horizon of antihypertensive treatment and will focus on 2 major areas of drug development. First, we will review novel targets for pharmacologic treatment and novel molecules and classes of drugs in various phases of development and recognize the limitations we face in their transition from research and development to clinical practice. Then, we will discuss an expanding array of combination strategies to better treat hypertension with the goal of minimizing the burden of cardiovascular and renal complications of hypertension.
高血压是最重要的心血管风险因素。我们见证了高血压治疗和控制的显著改善，以及可供临床医生和高血压专家选择的药物治疗方案的显著增加。高达三分之一的高血压患者血压未达到推荐的目标值，因此开发新的治疗方法以更好地治疗高血压至关重要。本综述将探讨不断扩大的抗高血压治疗领域，并重点关注药物开发的 2 个主要领域。首先，我们将回顾药物治疗的新靶点和处于不同开发阶段的新型分子和药物类别，并认识到它们从研发到临床实践的过程中所面临的局限性。然后，我们将讨论一系列不断扩大的联合治疗策略，以更好地治疗高血压，目标是最大限度地减少高血压心血管和肾脏并发症的负担。
